Trial Profile
TRANSORCE (A Sub-study of SORCE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cancer
- Focus Biomarker; Pharmacodynamics
- 16 Jun 2016 New trial record